Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classement en actions #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prix de l'action
$193.62
Capitalisation boursière
$150.08B
Changement (1 jour)
2.76%
Changement (1 an)
184.69%
Pays
GB
Échange AstraZeneca PLC (AZN)

Catégorie

Ratio P/B pour AstraZeneca PLC (AZN)
Ratio P/B au April 2026 TTM : 6.21
Selon les derniers rapports financiers et le cours de l'action de AstraZeneca PLC, le ratio cours/valeur comptable actuel (TTM) est 6.21. À la fin de 2023, le ratio P/B était de 5.38.
Historique du ratio P/B pour AstraZeneca PLC de 2000 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) 6.21 24.62%
2024 4.98 -7.57%
2023 5.38 -4.97%
2022 5.67 33.63%
2021 4.24 -49.52%
2020 8.40 -18.64%
2019 10.32 35.80%
2018 7.60 29.88%
2017 5.85 25.63%
2016 4.66 0.22%
2015 4.65 1.92%
2014 4.56 42.86%
2013 3.19 27.04%
2012 2.51 -7.17%
2011 2.71 -4.08%
2010 2.82 -14.38%
2009 3.30 -11.54%
2008 3.73 -14.17%
2007 4.34 -21.77%
2006 5.55 -4.09%
2005 5.79 37.69%
2004 4.20 -32.20%
2003 6.20 11.87%
2002 5.54 -4.09%
2001 5.78 -38.34%
2000 9.37 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
31.127 401.56%
US
7.2801 17.31%
US
-118.3879 -2,007.64%
US
6.2931 1.40%
CH
5.6944 -8.24%
US